分子靶向药物与免疫抑制剂联合治疗及其他联合治疗在肝细胞癌中的应用

Application of combined therapy with molecular-targeted drugs and immune checkpoint inhibitors and other combined therapies in hepatocellular carcinoma

肝细胞癌(HCC)是最常见的恶性肿瘤之一,发病隐匿,发展迅速,高复发的特点导致HCC患者长期生存面临巨大挑战。分子靶向药物与免疫抑制剂在HCC治疗中成为研究的热点,大量临床试验发现,联合治疗取得了不错的疗效。主要介绍了分子靶向药物与免疫抑制剂联合治疗及其他联合治疗在HCC中的应用,指出当前HCC治疗的最新研究热点在于系统治疗或局部治疗相关的联合治疗。

Hepatocellular carcinoma(HCC)is one of the most common malignant tumors,and its features of insidious onset,rapid development,and high recurrence bring great challenges to the long-term survival of HCC patients.Molecular-targeted drugs and immune checkpoint inhibitors have become the research hotspots in the treatment of HCC,and a large number of clinical trials have found that combined therapy has achieved a good clinical effect.This article mainly introduces the application of combined therapy with molecular-targeted drugs and immune checkpoint inhibitors and other combined therapies in HCC and points out that combined therapy related to systemic therapy or local therapy has become the latest research hotspot in HCC treatment.